Headache-Focused Biotech Raises $130M In Series A Round
Headache disorder-focused biotech Slate Medicines Inc., advised by Cooley LLP, on Tuesday revealed that it wrapped a Series A funding round with $130 million in tow....To view the full article, register now.
Already a subscriber? Click here to view full article